{"id":898231,"date":"2025-10-21T11:30:27","date_gmt":"2025-10-21T15:30:27","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/nexalins-difs-neurostimulation-shows-cognitive-and-brain-network-improvements-in-alzheimers-and-dementia-across-three-peer-reviewed-studies\/"},"modified":"2025-10-21T11:30:27","modified_gmt":"2025-10-21T15:30:27","slug":"nexalins-difs-neurostimulation-shows-cognitive-and-brain-network-improvements-in-alzheimers-and-dementia-across-three-peer-reviewed-studies","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/nexalins-difs-neurostimulation-shows-cognitive-and-brain-network-improvements-in-alzheimers-and-dementia-across-three-peer-reviewed-studies\/","title":{"rendered":"Nexalin\u2019s DIFS\u2122 Neurostimulation Shows Cognitive and Brain Network Improvements in Alzheimer\u2019s and Dementia Across Three Peer-Reviewed Studies"},"content":{"rendered":"

\nThree Independent Studies Published in \u201cAlzheimer\u2019s Research & Therapy,\u201d \u201cJournal of Alzheimer\u2019s Disease,\u201d and \u201cRadiology\u201d Validate Nexalin\u2019s Non-Invasive Approach with Consistent Cognitive and Neuroimaging Benefits
\n<\/h2>\n
\n

HOUSTON, TX, Oct. 21, 2025 (GLOBE NEWSWIRE) — Nexalin Technology, Inc. (Nasdaq: NXL)<\/b> (the \u201cCompany\u201d or \u201cNexalin\u201d), the leader in Deep Intracranial Frequency Stimulation (DIFS\u2122) of the brain, today announced that three independently published, peer-reviewed clinical studies, coupled with a growing body of internal data, collectively demonstrate the ability of its proprietary 15 milliamp (mA) Gen-2 Nexalin DIFS\u2122 technology\u2014to improve cognition, restore brain activity, and enhance neuron connectivity in patients with Alzheimer\u2019s disease (AD).<\/p>\n

Each study was announced separately upon publication. Taken together, the results provide a convergent body of evidence validating Nexalin\u2019s differentiated, non-invasive approach to treating Alzheimer\u2019s disease.<\/p>\n

\n 1. <\/b>
\n
\n TRANSFORM-AD \u2013 Alzheimer\u2019s Research & Therapy<\/i><\/b>
\n <\/a>
\n
This randomized, double-blind clinical trial (46 patients) evaluated 30 one-hour DIFS sessions over 15 days. Patients receiving active stimulation demonstrated immediate improvements in MMSE and MoCA scores, alongside enhanced hippocampal theta-gamma coupling and increased low-frequency fluctuations on fMRI. The study provided the first rigorous evidence of hippocampal activation and short-term cognitive benefit from DIFS in Alzheimer\u2019s and Dementia.<\/p>\n

\n 2. <\/b>
\n
\n Altered Neuronal Activity \u2013 Journal of Alzheimer\u2019s Disease<\/i><\/b>
\n <\/a>
\n
A subsequent publication used resting-state fMRI to analyze brain network changes. Results demonstrated significant increases in fALFF and regional homogeneity (ReHo) in key prefrontal and memory-related regions, including the left middle frontal gyrus and right parahippocampal gyrus. These findings underscored DIFS\u2019 ability to restore regional neuronal synchronization and blood flow in disrupted networks.<\/p>\n

\n 3. <\/b>
\n
\n Modulation of Cortical and Hippocampal Connectivity \u2013 Radiology<\/i><\/b>
\n <\/a>
\n
The most recent publication, appearing in Radiology<\/i> (June 2025), showed that DIFS significantly improved cognition while enhancing connectivity between the hippocampus and cortical regions, including the middle cingulate and middle frontal gyri. Network-level gains were also observed across the default mode and frontoparietal networks\u2014systems critical to memory and executive function. Notably, cognitive improvements correlated with imaging findings, directly linking brain network modulation to functional outcomes.<\/p>\n

With the global Alzheimer\u2019s market projected to exceed $20 billion annually, current treatments remain dominated by pharmacologic therapies targeting amyloid or tau proteins. These drugs, while representing some progress, often deliver modest clinical benefits, and carry significant safety risks and high costs.<\/p>\n

Nexalin\u2019s DIFS technology is fundamentally different:<\/p>\n